|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2001-2-16
|
|
pubmed:abstractText |
Systemic protamine sulfate for heparin reversal after cardiopulmonary bypass (CPB) is associated with uncommon, but life-threatening adverse reactions.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0003-4975
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
270-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Safety and efficacy of a heparin removal device: a prospective randomized preclinical outcomes study.
|
|
pubmed:affiliation |
Department of Surgery, University of Texas Medical Branch, Galveston 77555-0528, USA. jzwische@utmb.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Evaluation Studies
|
